Apic Bio, Inc. is a pioneering gene therapy company focused on developing novel treatment options for patients suffering from rare, monogenic disorders that have limited or no approved treatments. Operating in the biotechnology sector, Apic Bio serves patients and healthcare providers by leveraging its proprietary dual function silence and replace platform. This technology uses a single vector to simultaneously silence and replace damaged genes, offering a unique approach to gene therapy. The company primarily targets genetic conditions such as SOD1 ALS, for which it has received Orphan Drug Designation from the FDA. Apic Bio's business model revolves around research and development, clinical trials, and eventual commercialization of its gene therapy solutions. Revenue is generated through partnerships, grants, and potential future sales of approved therapies.

Keywords: gene therapy, rare diseases, monogenic disorders, SOD1 ALS, dual function platform, biotechnology, FDA Orphan Drug, genetic treatment, healthcare innovation, clinical trials.